RBC rates Pozen at outperform

Pozen, Inc. was rated at outperform, speculative risk, with a $15 price target, by RBC Capital Markets analyst Ken Trbovich on news of the company's road show to tout its accomplishments. The company's partnership with AstraZeneca for the PN program gave Pozen $40 million upfront and an additional $160 million in milestone payments. RBC believes the PN product has peak sales potential in excess of $1 billion. Other positives include Pozen's partnership with GlaxoSmithKline for Trexima, worth at least $20 million in milestone payments. Shares of the Chapel Hill, N.C.-based development-stage company were up 24 cents, or 1.32%, at $12.77. (Nasdaq: POZN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.